Iovance's Amtagvi Approved in Australia for Advanced Melanoma, Expanding Global Reach
IOVA has more than doubled off its 52-week low of $1.66.
Summary
Iovance Biotherapeutics secured conditional approval from Australia's TGA for Amtagvi (lifileucel) to treat advanced melanoma. This marks the company's third marketing authorization for the T-cell therapy and opens a significant new market, as Australia has the highest global rate of melanoma. This positive regulatory news follows the recent FDA clearance for IOV-5001 and strong Q1 financial results. The company is now establishing its first Australian treatment center, aiming to expand Amtagvi's global footprint.
At the time of this announcement, IOVA was trading at $3.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.66 to $5.63. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.